Index

VOLUME 6, 1993

Author Index

Ashford, W, 72

Baker, FM, 14, 66
Baker, K, 20
Bassett, SS, 105
Beaston-Wimmer, P, 161
Belzile, L, 120
Black, RS, 245
Blass, JP, 245
Blennow, K, 177
Bobholz, JH, 210
Brandt, J, 210
Broderick-Cantwell, J, 112
Brooks, JO, III, 235

Cambon, H, 200
Camille, Y, 120
Carey, RJ, 152
Coburn, KL, 72
Cohen, GD, 195
Cooper, JK, 29
Coyne, AC, 217
Cummings, JL, 144
Cutler, NR, 115

Dastoor, D, 120
Davis, S, 205
Deck, MDF, 245
DeLeo, B, 20
Derouesné, C, 200
DiLuca, C, 34
Du, W, 34
Duyckaerts, C, 200

Engel, P, 144

Fakouhi, D, 115
Fenn, HH, 235
Ferris, SH, 84
Figiel, GS, 20, 78
Flicker, C, 84
Fliesser, JM, 25
Folstein, MF, 105
Fricchione, GL, 25
Friedman, E, 161

Goewert, A, 20
Grime, G, 97
Growdon, JH, 34

Hauw, J-J, 200
Hendrie, HC, 115
Herting, RL, 115
Hoyer, S, 3

Janofsky, JS, 214
Jarvis, M, 20
Jones, BE, 66

Katz, IR, 161
Keller, I, 217
Kinscherf, DA, 78
Konishi, K, 131
Krishnan, KRR, 39
Kurita, A, 245

Landsberg, J, 97
Lartius, RK, 239
Lavizzo-Mourey, R, 66
Lawton, MP, 161
Loesberg, A, 217
Loring, D, 222
Lukovits, T, 230

Martens, C, 239
Matsuo, F, 115
Mattingly, G, 20
McDaniel, KD, 230
McDaniel, LD, 230
McDonald, B, 97
Meador, K, 222
Mellow, AM, 205
Mena, I, 144
Mezrich, RS, 217
Miller, TP, 235
Moore, E, 222
Moreno, MA, 72
Mulvihill, M, 137
Mungas, D, 29
Muraida, G, 14
Muraida, J, 14

Nastase, C, 120
Nichols, M, 222
Nolan, KA, 245

Parmelee, P, 161
Posas, H, 222
Powell, AL, 217

Rajput, A, 170
Rajput, AH, 170
Reisberg, B, 84
Rivner, M, 222
Rovner, BW, 214
Rozdilsky, B, 170
Rubin, EH, 78
Ruwitch, J, 20

Shuchter, SR, 137
Sledge, P, 137
Smith, DS, 20
Smith, WT, 115
Solano-Lopez, C, 205
Sramek, JJ, 115
Sugita, M, 131

Tachibana, H, 131
Thompson, E, 222
Tinklenberg, JR, 235
Toda, K, 131
Tueth, MJ, 112

Uemura, E, 239

Villanueva-Meyer, J, 144

Wallin, A, 177
Warren, BH, 14
Watt, F, 97
Woznicki, M, 25

Yassa, R, 120
Yelnik, A, 200
Yesavage, JA, 235

Zamrini, E, 222
Zervas, IM, 25
Zisook, S, 137
Zorumski, CF, 20, 78

Subject Index

African Americans, 66–70, 193–194, 195–199
Aging, 40–45, 84–95, 137–142, 196, 200–203
Albumin, 163–167
Aluminum, 239–243
Alzheimer's disease, 3–9, 29–33, 34–37, 59–60, 65, 72–76, 84–95, 115–119, 170–175, 192, 222–228, 230–233, 235–238, 252–253
Alzheimer's Disease Assessment Scale, 222–227
Amygdala, 51–52
Amyloid angiopathy, 179, 182
Atherosclerosis, 177–178

Basal ganglia, 50–54
Behavioral disorders, 205–208
Bereavement, 137–142
Binswanger's disease, 181
Blood-brain barrier damage, 179
Brain disorders, 3–9, 40–45, 49–50, 54, 179, 182, 192
Braking radiation, 103

California Alzheimer Disease Diagnostic and Treatment Center program, 29–30
Captopril, 112–114
Cardiovascular function, 20–24
Cerebral amyloid angiopathy, 182
Cerebral blood flow, 5–7, 145–150
Cerebral infarctions, 200–203
Cerebral metabolic rate, 5–7
Cerebral vascular mechanisms, 177–180
Cerebrovascular insufficiency, 179–180
Cochran-Mantel-Haenszel Test, 116–117
Cognitive function, 78–82, 84–95, 144–150, 210–213, 235–238
Computed tomography, 40–41, 45–46, 192, 245–249
Concomitant physical disease, 122
Confabulation, 27
Convex third ventricle, 217–220
Crying, pathological, 252

Death, age at, 202–203
Delusion, 121
Dementia, 3–9, 25–28, 29–33, 115–119, 126, 144–150, 177–184, 191–192, 205–208, 217–220, 222–228, 245–249
Dementia Rating Scale, 210–213
Depression, 39–54, 61, 192
Disability, 198
Dopamine, 52

Electroconvulsive therapy, 20–24, 78–82

Fluoxetine, 63

General Health Questionnaire, 106, 108
Geriatric Depression Scale, 78
Glutamatergic systems, 53
Granular cortical atrophy, 182

Hallucinations, 128
Haloperidol, 122–123
Hematologic indices, 163–167
Hemoglobin, 165–167
Hemorrhage, 180, 183
Hereditiary diseases, 183
Hippocampal neurons, 239–243
Hyalinosis, 178–179, 181–182
Hypertension, 32
Hyperviscosity, 180, 183
Hyponatremia, 112–114

Idiopathic Parkinson's disease, 170–175
Injuries, 128
Intracranial hemorrhage, 183
Ischemic disorders, 183, 245–249

Kruskal-Wallis Test, 117

Labetalol, 20–24
Lacunar dementia, 181
Laughing, pathological, 252
L-deprenyl, 252–253
Leukoencephalopathy, 46–49, 54
Levodopa, 152–159
Life expectancy, 189–190

Magnetic resonance imaging, 41–43, 46–49, 54, 217–220
Memory, 105–110, 127
Mental health, 195–199
Metabolism, 3–9
Milacemide, 115–119
Mini-Mental State Examination, 78–81, 106, 116, 124–125, 132, 144–150, 210–213, 223–227, 235–238
Mixed-type dementia, 183–184
Monoaminergic systems, 53
Monoamine systems, 52–53
Mortality rates, 163, 164
Motoric sensitization, 152–159
Multi-infarct dementia, 177, 180, 192

Neurobehavior Cognitive Status Examination, 144–150
Neurons, 239–243
Nifedipine, 20–24
NIMH-Diagnostic Interview Survey, 106
NMDA receptor, 8, 115–118
Norepinephrine, 52
Nuclear backscattering, 104
Nuclear microscopy, 97–103
Nursing home patients, 214–216

Oxford scanning proton microprobe, 98–99

P300 latency, 131–136
Panic disorder, 251
Parkinson's disease, 131–136, 152–159, 170–175
Particle-induced x-ray emission, 104
Patient Self-Determination Act, 214–216
Perfusion, 144–150
Physical health, 197–198
Polydipsia, 112–114
Premorbid personality, 122
Presbyophrenia, 25–28
Pseudodementia, 61
Psychotrophic drugs, 128

Reaction time, 131–136
Retirement planning, 14–19
Rochester Alzheimer's Disease Project, 230

Scanning transmission ion microscopy, 104
Scheffe's Multiple Range Test, 139
Schizophrenia, 120–125
Secondary electrons, 104
Senile dementia, 115–119
Senile plaques, 97–103
Serotonin, 52–53
Single-fiber electromyography, 223
Sodium valproate, 205–208
SPECT, 144–150
Stress, 3–9
Stroke, 49, 202, 252
Subcortical white-matter dementia, 181–182

Tacrine, 59–60
Tardive dyskinesia, 63
Thalamus, 217
Thiamine, 222–228
Thriving failure, 161–168
Thromboembolism, 177, 180

Vascular dementia, 29–33, 177–184
Vessel wall damage, 177–179, 181–182
Visual evoked potentials, 72–76

Weight loss, 34–37